Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
The Lancet. Haematology
|
July 30, 2021
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
Tapan M Kadia, Patrick K Reville, Gautam Borthakur, et al.
American Journal of Hematology
|
March 4, 2026
Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML
Jennifer Marvin-Peek, Hagop Kantarjian, Wei-Ying Jen, et al.
American Journal of Hematology
|
February 16, 2024
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups
Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, et al.
The Lancet. Haematology
|
September 5, 2022
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study
Alexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, et al.
British Journal of Haematology
|
August 23, 2023
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Ziyi Li, et al.
Leukemia
|
February 28, 2024
Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Juan Jose Rodriguez-Sevilla, David Michael Swanson, et al.
Blood Advances
|
April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
Curtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.
The Lancet. Haematology
|
March 7, 2024
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 7, 2024
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Rucha V Modak, Katia G de Oliveira Rebola, John McClatchy, et al.
Leukemia & Lymphoma
|
October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy
Jorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
The Lancet. Haematology
|
July 30, 2021
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
Tapan M Kadia, Patrick K Reville, Gautam Borthakur, et al.
American Journal of Hematology
|
March 4, 2026
Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML
Jennifer Marvin-Peek, Hagop Kantarjian, Wei-Ying Jen, et al.
American Journal of Hematology
|
February 16, 2024
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups
Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, et al.
The Lancet. Haematology
|
September 5, 2022
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study
Alexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, et al.
British Journal of Haematology
|
August 23, 2023
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Ziyi Li, et al.
Leukemia
|
February 28, 2024
Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Juan Jose Rodriguez-Sevilla, David Michael Swanson, et al.
Blood Advances
|
April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
Curtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.
The Lancet. Haematology
|
March 7, 2024
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 7, 2024
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Rucha V Modak, Katia G de Oliveira Rebola, John McClatchy, et al.
Leukemia & Lymphoma
|
October 20, 2021
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy
Jorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, et al.
Page
of 5